Classical and 3D-QSAR studies of cytochrome 17 inhibitor imidazole-substituted biphenyls

Molecular Simulation

Volumn 36, Issue 4, 2010, Pages 311-325

  Roy, Partha Pratim ^a   Roy, Kunal ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

LFER; MFA; MSA; QSAR; RSA

Indexed keywords

3D-QSAR; BEST MODEL; BIPHENYL DERIVATIVES; CHEMOMETRIC TOOLS; FUNCTION APPROXIMATION; HYDROGEN BOND DONORS; IMIDAZOLE GROUP; INHIBITORY ACTIVITY; INTERACTION POINTS; MOLECULAR FIELD ANALYSIS; MOLECULAR SHAPES; PARA POSITION; PARTIAL LEAST SQUARES; PHENYL RINGS; PREDICTIVE POWER; QSAR MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP; RECEPTOR SURFACE; RING SYSTEMS; RSA MODEL;

HYDROGEN BONDS; MOLECULAR GRAPHICS; SULFUR COMPOUNDS; SURFACE ANALYSIS;

THREE DIMENSIONAL;

EID: 77949479514     PISSN: 08927022     EISSN: 10290435     Source Type: Journal    
DOI: 10.1080/08927020903426493     Document Type: Article

References (62)

1. D.M. Parkin, Global cancer statistics in the year 2000, Lancet Oncol. 2 (2001), pp. 533-543.
2. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M.J. Thun, Cancer statistics, 2007, CA Cancer J. Clin. 57 (2007), pp. 43-66.
3. A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, A. Ghafoor, E.J. Feuer, and M.J. Thun, Cancer statistics, 2005, CA Cancer J. Clin. 55 (2005), pp. 10-30.
4. C. Huggins and C.V. Hodges, Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, Cancer Res. 1 (1941), pp. 293-297.
5. C. Huggins, R.E. Stevens, Jr, and C.V. Hodges, Studies on prostatic cancer: Ii. The effects of castration on advanced carcinoma of the prostate gland, Arch. Surg. 43 (1941), pp. 209-223.
6. I. Huhtaniemi, H. Nikula, M. Parvinen, and S. Rannikko, Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer, Am. J. Clin. Oncol. 11 (Suppl 1) (1988), pp. S11-S15.
7. J.A. Smith, New methods of endocrine management of prostatic cancer, J. Urol. 137 (1987), pp. 1-10.
8. E.D. Crawford, M.A. Eisenberger, D.G. McLeod, J.T. Spaulding, R. Benson, F.A. Dorr, B.A. Blumenstein, M.A. Davis, and P.J. Goodman, A controlled trial of leuprolide with and without flutamide in prostatic carcinoma, N. Engl. J. Med. 321 (1989), pp. 419-424.
9. C.D. Chen, D.S. Welsbie, C. Tran, S.H. Baek, R. Chen, R. Vessella, M.G. Rosenfeld, and C.L. Sawyers, Molecular determinants of resistance to antiandrogen therapy, Nat. Med. 10 (2004), pp. 33-39.
10. B.A. Hellerstedt and K.J. Pienta, The current state of hormonal therapy for prostate cancer, CA Cancer J. Clin. 52 (2002), pp. 154-179.
11. R. Arimoto, Computational models for predicting interactions with cytochrome p450 enzyme, Curr. Top. Med. Chem. 6 (2006), pp. 1609-1618.
12. E.M. Sellers, H.L. Kaplan, and R.F. Tyndale, Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking, Clin. Pharmacol. Ther. 68 (2000), pp. 35-43.
13. F.J. Gonzalez, Molecular genetics of the P-450 superfamily, Pharmacol. Ther. 45 (1990), pp. 1-38.
14. F.P. Guengerich, Characterization of human cytochrome P450 enzymes, FASEB J. 6 (1992), pp. 745-748.
15. S. Rendic, Summary of information on human CYPenzymes: Human P450 metabolism data, Drug Metabol. Rev. 34 (2002), pp. 83-448.
16. R.D. Bruno and V.C. Njar, Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development, Bioorg. Med. Chem. 15 (2007), pp. 5047-5060.
17. B.C. Chung, J. Picado-Leonard, M. Haniu, M. Bienkowski, P.F. Hall, J.E. Shively, and W.L. Miller, Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): Cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues, Proc. Natl Acad. Sci. USA 84 (1987), pp. 407-411.
18. M.K. Akhtar, S.L. Kelly, and M.A. Kaderbhai, Cytochrome b(5) modulation of 17{alpha} hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis, J. Endocrinol. 187 (2005), pp. 267-274.
19. N.W. Kolar, A.C. Swart, J.I. Mason, and P. Swart, Functional expression and characterisation of human cytochrome P45017alpha in Pichia pastoris, J. Biotechnol. 129 (2007), pp. 635-644.
20. K.A. Harris, V. Weinberg, R.A. Bok, M. Kakefuda, and E.J. Small, Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer, J. Urol. 168 (2002), pp. 542-545.
21. J. Eklund, M. Kozloff, J. Vlamakis, A. Starr, M. Mariott, L. Gallot, B. Jovanovic, L. Schilder, E. Robin, M. Pins, and R.C. Bergan, Phase II study of mitoxantrone and ketoconazole for hormonerefractory prostate cancer, Cancer 106 (2006), pp. 2459-2465.
22. R.A. Madan and P.M. Arlen, Abiraterone. Cougar biotechnology, IDrugs 9(1) (2006), pp. 49-55.
23. U.E. Hille, Q. Hu, C. Vock, M. Negri, M. Bartels, U. Müller-Vieira, T. Lauterbach, and R.W. Hartmann, Novel CYP17 inhibitors: Synthesis, biological evaluation, structure-activity relationships and modelling of methoxy-and hydroxy-substituted methyleneimidazolyl biphenyls, Eur. J. Med. Chem. 44 (2009), pp. 2765-2775.
24. J.G. Gambertoglio, W.J. Amend, Jr, and L.Z. Benet, Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: A review, J. Pharmacokinet. Biopharm. 8 (1980), pp. 1-52.
25. K. Fotherby, Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy, Contraception 54 (1996), pp. 59-69.
26. J.F. Steiner, Clinical pharmacokinetics and pharmacodynamics of finasteride, Clin. Pharmacokinet. 30 (1996), pp. 16-27.
27. A. Hameed, T. Brothwood, and P. Bouloux, Delivery of testosterone replacement therapy, Curr. Opin. Investig. Drugs 4 (2003), pp. 1213-1219.
28. J.E. Buster, P.R. Casson, A.B. Straughn, D. Dale, E.S. Umstot, N. Chiamori, and G.E. Abraham, Postmenopausal steroid replacement with micronized dehydroepiandrosterone: Preliminary oral bioavailability and dose proportionality studies, Am. J. Obstet. Gynecol. 166 (1992), pp. 1163-1168.
29. R.E. Peterson, Metabolism of adrenal cortical steroids, in The Human Adrenal Cortex, N.P. Christy, ed., Harper & Row, New York, 1997, pp. 87-189.
30. Q. Hu, M. Negri, K. Jahn-Hoffmann, Y. Zhuang, S. Olgen, M. Bartels, U. Müller-Vieira, T. Lauterbach, and R.W. Hartmann, Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)-part II: Core rigidification and influence of substituents at the methylene bridge, Bioorg. Med. Chem. 16 (2008), pp. 7715-7727.
31. C. Jagusch, M. Negri, U.E. Hille, Q. Hu, M. Bartels, K. Jahn-Hoffmann, M.A. Pinto-Bazurco Mendieta, B. Rodenwaldt, U. Müller-Vieira, D. Schmidt, T. Lauterbach, M. Recanatini, A. Cavalli, and R.W. Hartmann, Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure, Bioorg. Med. Chem. 16 (2008), pp. 1992-2010.
32. G.A. Wächter, R.W. Hartmann, T. Sergejew, G.L. Grün, and D. Ledergerber, Tetrahydronaphthalenes: Influence of heterocyclic substituents on inhibition of steroid enzymes P450 arom and P450 17, J. Med. Chem. 39 (1996), pp. 834-841.
33. F.C. Chan, G.A. Potter, S.E. Barrie, B.P. Haynes, M.G. Rowlands, J. Houghton, and M. Jarman, 3-and 4-pyridylalkyl adamantanecarboxylates: Inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer, J. Med. Chem. 39 (1996), pp. 3319-3323.
34. R. McCague, M.G. Rowlands, S.E. Barrie, and J. Houghton, Inhibition of enzymes of estrogen and androgen biosynthesis by esters of 4-pyridylacetic acid, J. Med. Chem. 33 (1990), pp. 3050-3055.
35. M.G. Rowlands, S.E. Barrie, F. Chan, J. Houghton, M. Jarman, R. McCague, and G.A. Potter, Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis, J. Med. Chem. 38 (1995), pp. 4191-4197.
36. R.W. Hartmann, G.A. Wächter, T. Sergejew, R. Würtz, and J. Düerkop, 4,5-Dihydro-3-(2-pyrazinyl)naphtho[1,2-c]pyrazole: A potent and selective inhibitor of steroid-17 alpha-hydroxylase-C17,20-lyase (P450 17), Arch. Pharm. (Weinheim) 328 (1995), pp. 573-575.
37. A.M. Al-Hamrouni, M. Ahmadi, P.J. Nicholls, H.J. Smith, P. Lombardi, and V. Pestellini, 1-[(Benzofuran-2-yl)phenylmethyl] imidazoles as inhibitors of 17a-hydroxylase: 17,20-lyase (P450 17): Species and tissue differences, Pharm. Sci. 3 (1997), pp. 259-263.
38. J.K. Yano, F. Blasco, H. Li, R.D. Schmid, A. Henne, and T.L. Poulos, Preliminary characterization and crystal structure of a thermostable cytochrome P450 from Thermus thermophilus, J. Biol. Chem. 278 (1) (2003), pp. 608-616.
39. B. Zhao, L. Lei, D.G. Vassylyev, X. Lin, D.E. Cane, and M.R. Waterman, A dual-function Cytochrome P450 170A1 from Streptomyces coelicolor. Available at http://www.ebi.ac.uk/ pdbsum/3dbg (accessed on November 5, 2009).
40. B.G. Wachall, M. Hector, Y. Zhuang, and R.W. Hartmann, Imidazole substituted biphenyls: A new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer, Bioorg. Med. Chem. 7 (1999), pp. 1913-1924.
41. C. Hansch and T. Fujita, r s p analysis: A method for the correlation of biological activity and chemical structure, J. Am. Chem. Soc. 86 (1964), pp. 1616-1626.
42. H. Kubinyi, in Methods and Principles in Medicinal Chemistry, M.E. Wolff, ed., Vol.1, VCH, Weinheim, 1993, pp. 497-571.
43. C. Hansch, A. Leo, and D. Hoekman, Exploring QSAR. Hydrophobic, Electronic and Steric Constants, American Chemical Society, Washington, DC, 1995.
44. Cerius2 version 4.10, A product of Accelrys, Inc., San Diego, USA; software available at http://www.accelrys.com/cerius2.
45. J.T. Leonard and K. Roy, On selection of training and test sets for the development of predictive QSAR models, QSAR Comb. Sci. 25 (2006), pp. 235-251.
46. A.J. Hopfinger and J.S. Tokarsi, Three-dimensional quantitative structure activity relationship analysis, in Practical Applications of Computer-Aided Drug Design, P.S. Charifson, ed., Marcel Dekker, New York, 1997, pp. 105-164.
47. A. Hirashima, T. Eiraku, E. Kuwano, and M. Eto, Threedimensional molecular field analyses of agonists for tyramine receptor which inhibit sex-pheromone production in Plodia interpunctella, Internet Electron. J. Mol. Des. 2 (2003), pp. 511-526.
48. M. Hahn, Receptor surface models. 1. Definition and construction, J. Med. Chem. 38 (1995), pp. 2080-2090.
49. Y. Fan, L.M. Shi, K.W. Kohn, Y. Pommier, and J.N. Weinstein, Quantitative structure-antitumor activity relationships of camptothecinanalogues: Cluster analysis and genetic algorithm-based studies, J. Med. Chem. 44 (2001), pp. 3254-3263.
50. D. Rogers and A.J. Hopfinger, Application of genetic function approximation to quantitative structure-activity relationship and quantitative structure-property relationship, J. Chem. Inf. Comput. Sci. 34 (1994), pp. 854-866.
51. W.J. Dunn III and D. Rogers, Genetic partial least squares in QSAR, in Genetic Algorithms in Molecular Modeling, J. Devillers, ed., Academic Press, London, 1996, pp. 109-130.
52. K. Hasegawa, Y. Miyashita, and K. Funatsu, GA strategy for variable selection in QSAR studies: GA-based PLS analysis of calcium channel antagonists, J. Chem. Inf. Comput. Sci. 37 (1997), pp. 306-310.
53. G.W. Snedecor and W.G. Cochran, Statistical Methods, Oxford & IBH Publishing Co. Pvt. Ltd, New Delhi, 1967.
54. S. Wold, PLS for multivariate linear modeling, in Chemometric Methods in Molecular Design, H. van de Waterbeemd, ed., VCH, Weinheim, 1995, pp. 195-218.
55. A.K. Debnath, Quantitative structure-activity relationship (QSAR): A versatile tool in drug design, in Combinatorial Library Design and Evaluation: Principles, Software Tools, and Applications in Drug Discovery, A.K. Ghose and V.N. Viswanadhan, eds., Marcel Dekker, New York, 2001, pp. 73-129.
56. K. Roy, On some aspects of validation of predictive QSAR models, Expert. Opin. Drug. Discov. 2 (2007), pp. 1567-1577.
57. P.P. Roy and K. Roy, On some aspects of variable selection for partial least squares regression models, QSAR Comb. Sci. 27 (2008), pp. 302-313.
58. K. Roy and P.P. Roy, Comparative QSAR studies of CYP1A2 inhibitor flavonoids using 2D and 3D descriptors, Chem. Biol. Drug Des. 72 (2008), pp. 370-382.
59. P.P. Roy, S. Paul, I. Mitra, and K. Roy, On two novel parameters for validation of predictive QSAR models, Molecules 14 (2009), pp. 1660-1701.
60. K. Roy and S. Paul, Exploring 2D and 3D QSARs of 2,4-diphenyl-1,3- oxazolines for ovicidal activity against Tetranychus urticae, QSAR Comb. Sci. 28 (4) (2008), pp. 406-425.
61. P.P. Roy, J.T. Leonard, and K. Roy, Exploring the impact of the size of training sets for the development of predictive QSAR models, Chemom. Intell. Lab. Sys. 90 (2008), pp. 31-42.
62. L. Eriksson, J. Jaworska, A.P. Worth, M.T. Cronin, R.M. McDowell, and P. Gramatica, Methods for reliability and uncertainty assessment and for applicability evaluations of classification-and regression-based QSARs, Environ. Health. Perspect. 111 (2003), pp. 1361-1375.